Abstract Details

<< Back to Detailed Agenda

8/23/2022  |   10:45 AM - 11:10 AM   |  Confederation II/III

National Congenital CMV (cCMV) Disease Registry - Texas Cases - Maternal Age is a Significant Risk F

Of 449 cCMV births in the state of Texas from 1982-2022 from the National Congenital CMV Disease Registry, 219 (49%) mothers were under age 25. Maternal age < 25 was a risk factor for prematurity (OR = 1.57, 95% CI = 1.04 to 2.37, p = .033) and low birthweight (LBW)(< 2500g) (OR = 2.40, 95% CI = 1.61 to 3.58, p < .001). Infants of younger non-Hispanic Black and White mothers, but not Hispanic mothers, had higher rates of prematurity, LBW and small-for-gestational-age (SGA) compared to mothers ? 25. Infants with LBW had significantly more cCMV symptoms than normal-weight infants: (mean (SD) symptoms = 5.0 (3.5) vs. 2.7 (2.7), p < .001); were more likely to have nervous system-related symptoms (62% vs 40%, p < .001) and liver-related symptoms (46.7% vs. 24.5%, p < .001) compared to normal-weight infants. Preterm infants (<37 weeks) also had more cCMV symptoms (mean (SD) = 4.6 (3.6) vs. 3.1 (3.1), p < .001), were more likely to have nervous system-related symptoms (60% vs 46%, p = .005) and liver-related symptoms (74% vs. 53%, p = .001) than term infants. Results indicate more severe cCMV disease in births to younger mothers, and suggest targets for prevention of cCMV and its adverse birth outcomes.

  • Understand younger maternal age as a risk factor for more severe cCMV disease and adverse birth outcomes
  • Low birthweight and premature birth increase risk of more cCMV symptoms at birth
  • Identify targets for prevention of cCMV and its adverse birth outcomes

Presentation:
This presentation has not yet been uploaded.

Handouts:
No handouts have been uploaded.

Session Evaluation


Gail Demmler-Harrison (), gdemmler@bcm.edu;
Professor of Pediatrics at Baylor College of Medicine with over 30 years experience in the research and clinical management of infants with congenital CMV infection; PI of the HOuston Longitudinal Congenital CMV Followup Study; co author or author of numerous publicaitons, chapters and presenter at national and international meetings

      ASHA DISCLOSURE:

Financial - Receives Royalty options or other ownership interest for Other activities from Elsevier Publisher.   Receives Consulting fee,Grants for Consulting,Membership on advisory committee or review panels,Independent contractor from Merck.   Receives Consulting fee,Grants for Independent contractor from Microgen.   Receives Consulting fee for Consulting,Membership on advisory committee or review panels from Moderna.   Receives Royalty options or other ownership interest for Other activities from UpToDate.   Receives Honoraria excluding diversified mutual funds,Speaker for Other activities from WebMD Medscape.  

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - Receives support from Merck, Moderna, Microgen, Elsevier, UpToDate, WebMD for Royalties for writing, Consulting, Speaking, Research.